LGD-4033 vs Methylene Blue
Moderate Research vs Well Studied
avoid Mechanism-based · 64% Both LGD-4033 and Methylene Blue carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
LGD-4033 Methylene Blue
Weight 338.25 Da 319.85 Da
Half-life ~24-36 hours ~5-6 hours
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) Phenothiazine dye (C16H18ClN3S)
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Methylene Blue
01 Enhances mitochondrial respiration and ATP production by acting as an alternative electron carrier
02 Reduces mitochondrial reactive oxygen species generation
03 Supports memory consolidation and cognitive performance at low doses
04 Neuroprotective effects demonstrated in models of Alzheimer's, Parkinson's, and traumatic brain injury
05 Improves mitochondrial function in aging cells and tissues
06 FDA-approved treatment for acquired methemoglobinemia
07 Anti-inflammatory and antimicrobial properties
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Methylene Blue
Blue or blue-green discoloration of urine (expected and harmless)
Blue-green staining of the tongue and mouth with liquid formulations
Mild nausea or stomach discomfort, especially at higher doses
Blue discoloration of stool
Mild headache during initial use
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Concurrent use of SSRIs, SNRIs, or MAO inhibitors (serotonin syndrome risk)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk of severe hemolytic anemia)
Renal insufficiency (methylene blue is primarily renally excreted)
Known hypersensitivity to methylene blue or phenothiazine compounds
Pregnancy and breastfeeding (insufficient safety data)
Research Evidence
LGD-4033 Methylene Blue
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest 2018 2017
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.